Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH ...

PART I [Key Information](index=4&type=section&id=Item%203.%20Key%20Information) The company faces significant financial, operational, and securities-related investment risks [Risk Factors](index=4&type=section&id=D.%20Risk%20factors) Financial vulnerability is highlighted by historical net losses, funding dependency, and clinical trial risks - The company has a history of significant net losses and anticipates continued losses, with no revenue from product sales[25](index=25&type=chunk) Net Losses for Fiscal Years 2020-2022 | Fiscal Year Ended June 30 | Net Loss (A$ million) | | :--- | :--- | | 2020 | 12.5 | | 2021 | 8.4 | | 2022 | 24.6 | - As of June 30, 2022, the company had **accumulated losses of A$68.3 million**[26](index=26&type=chunk) - The company's ability to continue as a going concern depends on raising additional capital, with cash sufficient only until **Q1 CY2023**[40](index=40&type=chunk)[41](index=41&type=chunk) - Lead programs **paxalisib and EVT801** face risks of clinical trial failure or unexpected safety concerns[33](index=33&type=chunk)[34](index=34&type=chunk) - There is a risk the company may be classified as a **Passive Foreign Investment Company (PFIC)**, creating adverse U.S. tax consequences[88](index=88&type=chunk) - The company's ADSs could be **delisted from NASDAQ** if the share price remains below US$1.00 for 30 consecutive business days[86](index=86&type=chunk) [Information on the Company](index=16&type=section&id=Item%204.%20Information%20on%20the%20Company) Kazia Therapeutics is an oncology-focused biotech developing drug candidates through a model of licensing and collaboration [Business Overview](index=17&type=section&id=B.%20Business%20overview) The company's oncology pipeline is led by paxalisib for brain cancer and EVT801 for advanced solid tumors - The lead drug candidate is **paxalisib**, a PI3K / AKT / mTOR pathway inhibitor in eight active clinical trials for brain cancers[95](index=95&type=chunk) - The second clinical asset is **EVT801**, a VEGFR3 inhibitor, which commenced a Phase I trial in November 2021[97](index=97&type=chunk)[98](index=98&type=chunk)[125](index=125&type=chunk) - Paxalisib has received multiple FDA special designations, including **Orphan Drug, Fast Track, and Rare Pediatric Disease Designations**[108](index=108&type=chunk) - Phase II data for paxalisib showed a median overall survival of **15.7 months**, comparing favorably to the standard of care (12.7 months)[109](index=109&type=chunk) - Post-period, the paxalisib arm of the **GBM AGILE study did not meet pre-defined criteria** to advance to a second stage[113](index=113&type=chunk) - An "at-the-market" (ATM) equity program was established in May 2022, raising **gross proceeds of US$2.95 million** by June 30, 2022[163](index=163&type=chunk) [Organizational Structure](index=27&type=section&id=C.%20Organizational%20structure) The Australian parent company operates through wholly-owned subsidiaries in Australia, the United States, and Hong Kong Wholly-Owned Subsidiaries | Name | Country of incorporation | | :--- | :--- | | Kazia Laboratories Pty Ltd | Australia | | Kazia Research Pty Ltd | Australia | | Kazia Therapeutics Inc. | United States (Delaware) | | Glioblast Pty Ltd | Australia | | Kazia Therapeutics (Hong Kong) Limited | Hong Kong | [Operating and Financial Review and Prospects](index=28&type=section&id=Item%205.%20Operating%20and%20Financial%20Review%20and%20Prospects) The company's net loss increased significantly in FY2022 due to higher R&D expenses and a lack of licensing revenue [Operating Results](index=28&type=section&id=A.%20Operating%20results) The net loss widened to A$24.6 million in FY2022, driven by increased R&D spending and no licensing revenue Summary of Revenue and Other Income (A$'000) | | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | Revenue | — | 15,183 | — | | Finance income | — | 42 | 66 | | Other income | 25 | 2 | 995 | | **Total revenue and other income** | **25** | **15,227** | **1,061** | - R&D expenses **increased by 39% to A$20.3 million** in FY2022, driven by clinical trials for paxalisib and EVT801[173](index=173&type=chunk) - General and administrative costs **decreased by 36% to A$4.5 million** in FY2022, partly due to a prior-year tax expense[173](index=173&type=chunk) - The **net loss after tax increased to A$24.6 million** in FY2022 from A$8.4 million in FY2021[174](index=174&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=B.%20Liquidity%20and%20capital%20resources) The company's liquidity is constrained, with its going concern status dependent on raising additional capital via equity - As of June 30, 2022, the company had **cash of A$7.4 million** and **accumulated losses of A$68.3 million**[176](index=176&type=chunk)[177](index=177&type=chunk) Cash Flow Summary (A$'000) | | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | Net cash used in operating activities | (22,763) | (9,111) | (8,810) | | Net cash from investing activities | (2,365) | — | — | | Net cash from financing activities | 3,726 | 28,109 | 12,139 | - In FY2022, the company issued **6,743,167 ordinary shares**, primarily through its ATM facility and a convertible note conversion[188](index=188&type=chunk) - The Triaxial convertible note was fully converted into **1,855,357 ordinary shares** on May 5, 2022[191](index=191&type=chunk) [Research and Development](index=31&type=section&id=C.%20Research%20and%20development,%20Patents%20and%20Licenses,%20etc.) R&D spending has steadily increased, driven by clinical trial costs for the company's lead product candidates Company-Sponsored R&D Spending (A$ million) | Fiscal Year | R&D Spending | | :--- | :--- | | 2020 | 9.5 | | 2021 | 14.5 | | 2022 | 20.3 | - R&D expenses primarily cover costs for developing product candidates, including clinical trial expenses and manufacturing[193](index=193&type=chunk) [Directors, Senior Management and Employees](index=32&type=section&id=Item%206.%20Directors,%20Senior%20Management%20and%20Employees) The company is led by an experienced board and management team, with compensation tied to performance incentives [Compensation](index=35&type=section&id=B.%20Compensation) Executive remuneration combines fixed salary, cash bonuses, and long-term equity incentives through an employee option plan - The executive remuneration framework consists of fixed remuneration, short-term cash bonuses, and long-term share-based payments[212](index=212&type=chunk) FY2022 Key Management Personnel Compensation (A$) | Name | Role | Salary & fees | Bonus | Share-based payments | Total | | :--- | :--- | :--- | :--- | :--- | :--- | | I Ross | Chairman | 150,546 | — | 46,159 | 196,705 | | B Carmine | Non-Exec Director | 85,000 | — | 46,159 | 139,659 | | S Coffey | Non-Exec Director | 85,000 | — | 46,159 | 139,659 | | J Garner | CEO | 530,500 | 325,000 | 1,015,198 | 2,004,227 | | J Friend | CMO | 430,279 | 201,978 | 250,194 | 943,606 | | K Krumeich | CFO | 277,972 | — | 100,331 | 399,882 | | **Total** | | **1,858,798** | **577,978** | **1,559,930** | **4,264,968** | - During fiscal year 2022, the company issued **4,800,000 share options** under its ESOP, with 4,200,000 granted to Key Management Personnel[220](index=220&type=chunk) [Board Practices](index=39&type=section&id=C.%20Board%20Practices) The board comprises a majority of independent directors and operates with two key committees for governance and oversight - The Board comprises four directors, **three of whom are independent non-executive directors**[238](index=238&type=chunk)[243](index=243&type=chunk) - The Board has two key committees: the **Audit, Risk and Governance Committee** and the **Remuneration and Nomination Committee**[246](index=246&type=chunk)[247](index=247&type=chunk)[249](index=249&type=chunk) - Directors must retire and stand for re-election at least **every three years**[241](index=241&type=chunk) [Employees](index=44&type=section&id=D.%20Employees) The company's employee base has grown, particularly in R&D and in the United States, to support expanding operations Full-Time Equivalent Employees by Year and Location | Category | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | **By Activity** | | | | | Research and Development | 6.8 | 4.6 | 3.6 | | Finance and Administration | 2.2 | 1.7 | 1.7 | | **Total** | **9.0** | **6.3** | **5.3** | | **By Location** | | | | | Australia | 5.0 | 5.3 | 5.3 | | United States | 4.0 | 1.0 | 0.0 | | **Total** | **9.0** | **6.3** | **5.3** | [Share Ownership](index=44&type=section&id=E.%20Share%20Ownership) Key Management Personnel collectively hold a minority stake in the company through shares and options KMP Shareholdings as of June 30, 2022 | Name | Balance at start of year | Purchased | Exercise of options | Balance at end of year | | :--- | :--- | :--- | :--- | :--- | | B Carmine | 372,693 | 47,169 | — | 419,862 | | S Coffey | 434,265 | 50,000 | — | 484,265 | | I Ross | 1,000,001 | 75,000 | — | 1,075,001 | | J Garner | 430,000 | 70,000 | — | 500,000 | | K Hill | 295,000 | — | 25,000 | 320,000 | | **Total** | **2,645,127** | **242,169** | **25,000** | **2,799,128** | KMP Option Holdings as of June 30, 2022 | Name | Balance at start of year | Granted | Exercised | Balance at end of year | | :--- | :--- | :--- | :--- | :--- | | J Garner | 2,000,000 | 2,500,000 | — | 4,500,000 | | K Hill | 125,000 | 100,000 | (25,000) | 200,000 | | I Ross | 400,000 | — | — | 400,000 | | B Carmine | 400,000 | — | — | 400,000 | | S Coffey | 400,000 | — | — | 400,000 | | J Friend | — | 800,000 | — | 800,000 | | K Krumeich | — | 800,000 | — | 800,000 | | **Total** | **3,520,500** | **4,300,000** | **(25,000)** | **7,500,000** | [Major Shareholders and Related Party Transactions](index=45&type=section&id=Item%207.%20Major%20Shareholders%20and%20Related%20Party%20Transactions) Hyecorp is the only substantial shareholder, and no significant related party transactions occurred in FY2022 5% or Greater Shareholders' Ownership | Shareholder | Oct 7, 2022 (%) | Sep 30, 2021 (%) | Aug 14, 2020 (%) | | :--- | :--- | :--- | :--- | | Hyecorp | 12.7% | 14.44% | 16.1% | | Platinum Int'l Healthcare Fund | <5% | 5.47% | 9.9% | | Quest Asset Partners Pty Ltd | <5% | 8.4% | 6.3% | - As of October 7, 2022, **40.0% of the company's outstanding ordinary shares** were held in the form of ADSs[262](index=262&type=chunk) - The company did not enter into any **significant transactions or loans with related parties** during fiscal year 2022[264](index=264&type=chunk) [Financial Information](index=46&type=section&id=Item%208.%20Financial%20Information) The company's full financial statements are provided elsewhere, with no dividends paid or significant subsequent events - Consolidated financial statements are included in **Item 18** of this report[267](index=267&type=chunk) - **No dividends were paid**, recommended, or declared during fiscal years 2022, 2021, or 2020[269](index=269&type=chunk) - **No significant changes** have occurred since the date of the annual financial statements included in this report[270](index=270&type=chunk) [The Offer and Listing](index=46&type=section&id=Item%209.%20The%20Offer%20and%20Listing) The company's securities are dual-listed on the ASX in Australia and the NASDAQ in the United States - The company's ordinary shares are listed on the **Australian Securities Exchange (ASX)** with the trading symbol 'KZA'[273](index=273&type=chunk) - The company's American Depositary Shares (ADSs) trade on the **NASDAQ Capital Market** under the symbol 'KZIA'[274](index=274&type=chunk) [Additional Information](index=46&type=section&id=Item%2010.%20Additional%20Information) This section details material contracts, regulatory frameworks, and key tax considerations for investors [Material Contracts](index=51&type=section&id=C.%20Material%20contracts) The company's operations are underpinned by key licensing and clinical trial agreements with global partners - Entered a worldwide licensing agreement with **Genentech** in October 2016 to develop and commercialize paxalisib[307](index=307&type=chunk) - Entered a clinical trial agreement with **GCAR** in October 2020 for paxalisib's inclusion in the GBM AGILE trial[313](index=313&type=chunk) - In March 2021, licensed Cantrixil to **Vivesto AB** for an upfront payment of US$4 million and future milestones[315](index=315&type=chunk) - In March 2021, licensed paxalisib to **Simcere** for Greater China, receiving an upfront payment of US$11 million[316](index=316&type=chunk) - In April 2021, licensed EVT801 from **Evotec SE** for a €1 million upfront payment and future milestones[317](index=317&type=chunk) [Taxation](index=53&type=section&id=E.%20Taxation) U.S. investors face a significant risk of adverse tax consequences due to the company's likely PFIC status - The company believes it may be treated as a **Passive Foreign Investment Company (PFIC)** for U.S. tax purposes[339](index=339&type=chunk) - If classified as a PFIC, U.S. holders would be subject to a **special tax regime on "excess distributions" and gains**[340](index=340&type=chunk) - For Australian tax purposes, dividends paid to non-Australian shareholders are subject to a **30% withholding tax** on unfranked portions[356](index=356&type=chunk) - Non-Australian shareholders are generally **exempt from Australian capital gains tax** on the disposal of shares[357](index=357&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=59&type=section&id=Item%2011.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company is primarily exposed to interest rate, credit, and foreign currency risks, which it manages without derivatives - The company's primary market risks are **interest rate risk, credit risk, and foreign currency risk** (mainly USD)[374](index=374&type=chunk)[375](index=375&type=chunk)[378](index=378&type=chunk) - As of June 30, 2022, the company **did not use derivative financial instruments** for hedging[379](index=379&type=chunk) [Description of Securities Other than Equity Securities](index=60&type=section&id=Item%2012.%20Description%20of%20Securities%20Other%20than%20Equity%20Securities) Investors in the company's American Depositary Shares are subject to various fees charged by the depositary bank American Depositary Share (ADS) Fees | Fee | For | | :--- | :--- | | US$5.00 (or less) per 100 ADSs | Issuance or cancellation of ADSs | | US$.05 (or less) per ADS | Any cash distribution | | US$.05 (or less) per ADS per calendar year | Depositary services | | Taxes and governmental charges | As incurred (e.g., stamp duty, withholding taxes) | PART II [Controls and Procedures](index=61&type=section&id=Item%2015.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and internal control over financial reporting were effective - Management concluded that the company's **disclosure controls and procedures were effective** as of June 30, 2022[390](index=390&type=chunk) - Management concluded that the company's **internal control over financial reporting was effective** as of June 30, 2022[391](index=391&type=chunk) - **No material changes** in internal control over financial reporting occurred during the period[396](index=396&type=chunk) [Audit Committee Financial Expert](index=61&type=section&id=Item%2016A.%20Audit%20Committee%20Financial%20Expert) The Board has determined that independent director Steven Coffey qualifies as an audit committee financial expert - The Board has identified **Steven Coffey** as the "audit committee financial expert"[397](index=397&type=chunk) - Steven Coffey is an **independent director and qualified Chartered Accountant** with over 30 years of public practice experience[397](index=397&type=chunk) [Code of Ethics](index=62&type=section&id=Item%2016B.%20Code%20of%20Ethics) The company has adopted a Code of Ethics and Business Conduct that applies to all personnel - The company has adopted a **Code of Ethics and Business Conduct** applicable to all directors, management, and employees[398](index=398&type=chunk) [Principal Accounting Fees and Services](index=62&type=section&id=Item%2016C.%20Principal%20Accounting%20Fees%20and%20Services) Grant Thornton served as the independent auditor, with all services pre-approved by the Audit Committee Audit Fees (A$'000) | | 2022 | 2021 | | :--- | :--- | :--- | | Audit fees - Grant Thornton Audit Pty Ltd | 181 | 151 | - The Audit Committee **pre-approves 100% of all audit** and permitted non-audit services[402](index=402&type=chunk) [Corporate Governance](index=63&type=section&id=Item%2016G.%20Corporate%20Governance) As a foreign private issuer, the company follows Australian governance practices in lieu of certain NASDAQ rules - As a foreign private issuer, the company is **exempt from certain SEC rules**, including proxy and short-swing profit reporting[406](index=406&type=chunk) - The company utilizes NASDAQ exemptions to **follow Australian corporate governance practices**[407](index=407&type=chunk)[408](index=408&type=chunk) PART III [Financial Statements](index=64&type=section&id=Item%2018.%20Financial%20Statements) The auditor's report raises substantial doubt about the company's ability to continue as a going concern [Report of Independent Registered Public Accounting Firm](index=68&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) The auditor's report highlights a going concern uncertainty and critical audit matters related to intangible assets - The auditor's report includes a **'Going Concern' paragraph**, citing recurring losses and negative cash flow[420](index=420&type=chunk) - **Critical Audit Matters** identified were the impairment assessment of intangible assets and the valuation of contingent consideration[424](index=424&type=chunk)[425](index=425&type=chunk)[429](index=429&type=chunk) [Consolidated Financial Statements](index=70&type=section&id=Consolidated%20Financial%20Statements) The company reported a net loss of A$24.6 million for FY2022, leading to a significant decrease in net assets Consolidated Statement of Profit or Loss (A$'000) | | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | Revenue from continuing operations | — | 15,183 | — | | Research and development expense | (20,252) | (14,541) | (9,494) | | General and administrative expense | (4,512) | (7,022) | (3,690) | | **Loss after income tax expense for the year** | **(24,648)** | **(8,422)** | **(12,467)** | Consolidated Statement of Financial Position (A$'000) | | 2022 | 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | 7,361 | 27,587 | | Intangibles | 20,050 | 22,003 | | **Total assets** | **34,958** | **58,088** | | **Liabilities** | | | | Trade and other payables | 3,760 | 4,933 | | Contingent consideration | 9,515 | 12,091 | | **Total liabilities** | **16,320** | **20,237** | | **Net assets** | **18,638** | **37,851** | Earnings Per Share (Cents) | | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | Basic earnings per share | (18.61) | (7.16) | (17.07) | | Diluted earnings per share | (18.61) | (7.16) | (17.07) | [Notes to the Financial Statements](index=75&type=section&id=Notes%20to%20the%20financial%20statements) Key disclosures include material uncertainty over going concern status and critical estimates for intangible assets - The financial statements were prepared on a going concern basis, but **material uncertainty exists** due to dependency on future funding[444](index=444&type=chunk)[445](index=445&type=chunk)[446](index=446&type=chunk) - **Critical accounting judgments** include R&D expense timing, share-based payment valuation, and intangible asset impairment[529](index=529&type=chunk)[530](index=530&type=chunk)[533](index=533&type=chunk) Intangible Assets Breakdown (A$'000) | Licensing Agreement | 2022 Carrying Value | 2021 Carrying Value | | :--- | :--- | :--- | | Paxalisib | 10,241 | 11,326 | | EVT-801 | 9,809 | 10,677 | | **Total** | **20,050** | **22,003** | Contingent Consideration (A$'000) | Liability Type | 2022 | 2021 | | :--- | :--- | :--- | | Current | 759 | 3,165 | | Non-current | 8,756 | 8,927 | | **Total** | **9,515** | **12,091** | - During FY2022, **4,800,000 options were granted** under the ESOP, with a total share-based payment expense of $1,674,581[624](index=624&type=chunk)[629](index=629&type=chunk) - Post-period end, the company was advised the **paxalisib arm of the GBM AGILE study did not meet criteria to proceed**[638](index=638&type=chunk)[639](index=639&type=chunk)

Financial Performance - Kazia concluded FY2022 with a cash balance of $7.4 million, down from $27.6 million at the end of FY2021[18]. - Total assets decreased to $35 million in FY2022, compared to $58 million in FY2021[18]. - The consolidated entity reported a loss of $24,647,815 for the year ended June 30, 2022, compared to a loss of $8,421,960 for the previous year, indicating a significant increase in losses[108]. - Total revenue for the year ended June 30, 2022, was $15,182,711, compared to $15,182,711 in 2021[178]. - The net loss after income tax for the year was $24,647,815, compared to a loss of $8,421,960 in 2021, indicating a significant increase in losses[178]. - Cash and cash equivalents decreased to $7,361,112 from $27,586,760, representing a decline of approximately 73%[180]. - Total liabilities decreased to $16,320,475 from $20,236,320, a decline of approximately 19%[180]. - Net assets fell to $18,638,287 from $37,850,719, indicating a decrease of about 51%[180]. - The company reported a total comprehensive loss of $24,613,200 for the year, compared to a loss of $8,420,092 in the previous year[178]. - Cash flows from operating activities resulted in a net cash outflow of $22,762,663, significantly higher than the previous year's outflow of $9,110,516[185]. Research and Development - The company invested $22 million in R&D during FY2022, representing over 80% of total expenditures for the year[18]. - Kazia's lead program, paxalisib, has shown encouraging results in its Phase II study for glioblastoma, with significant efficacy data reported[29]. - The Phase II study of paxalisib in glioblastoma has completed recruitment, and the GBM AGILE pivotal study is ongoing, with final data anticipated in 2H CY2023[62]. - Positive signals have been observed in a study of paxalisib combined with radiotherapy for brain metastases, with every evaluable patient showing a radiological response[29]. - Kazia is preparing for a potential regulatory filing for paxalisib, with a pivotal study success rate of over 90% for commercial product approval[64]. - The GBM AGILE pivotal study's paxalisib arm has completed recruitment, with final analysis expected in 2H CY2023[128]. - The company is conducting a Phase II study of paxalisib in combination with trastuzumab for HER2+ breast cancer brain metastases, with initial interim efficacy data expected in 2H CY2022[123]. - The company is also developing EVT801, a selective inhibitor of VEGFR3, which is currently in a phase 1 study that began recruitment in November 2021[108]. Clinical Trials and Drug Development - Paxalisib is involved in eight ongoing clinical trials across four distinct disease areas, with promising outcomes reported in studies of brain metastases[17]. - The first stage of the GBM AGILE pivotal trial for paxalisib has achieved full recruitment, with final data expected in 2H CY2023[15]. - Two new clinical trials for paxalisib have commenced: one at Weill Cornell Medicine and another in collaboration with the Pacific Pediatric Neuro-Oncology Consortium[28]. - The GBM AGILE study has screened over 1,000 patients, exceeding Kazia's expectations for recruitment pace[63]. - The Phase II genomically-guided study of paxalisib in brain metastases has progressed to an expansion stage for breast cancer[124]. - Interim data from a Phase I study of paxalisib in combination with whole brain radiotherapy shows a 100% overall response rate (ORR) among 9 evaluable patients[126]. Strategic Partnerships and Market Opportunities - Kazia has licensed the Greater China region to Simcere Pharmaceutical to expedite paxalisib's entry into China, marking a strategic partnership[69]. - Kazia's focus on brain metastases represents a significant market opportunity, with over 200,000 patients developing brain metastases annually in the U.S.[54]. - The US market typically accounts for 45-50% of the commercial value of a new cancer drug, highlighting the economic importance of this territory[72]. - Kazia's strategy includes implementing an 'at-the-market' (ATM) facility to provide interim access to capital during market downturns[21]. Corporate Governance and Financial Management - Kazia has launched a new ESG framework to enhance corporate responsibility and sustainability practices[80]. - The company is committed to high standards of corporate governance, respecting frameworks of both ASX and NASDAQ[86]. - The company has no dividends paid, recommended, or declared during the current or previous financial year, indicating a focus on reinvestment into R&D[108]. - The total remuneration for key management personnel (KMP) amounted to AUD 4,264,968 for the financial year ended 30 June 2022[146]. - The company aims to align executive interests with shareholders through equity-based payments that vest in tranches based on tenure[143]. Financial Position and Equity - The enterprise value of the company rose significantly to AUD 145,349,234 in June 2022, compared to AUD 34,751,206 in June 2021, marking a 318% increase[149]. - The number of share options issued to KMP increased to 4,300,000 in 2022 from 2,100,000 in 2021, reflecting a 104.76% increase[149]. - The company issued shares totaling $4,202,222 during the year, with share issue costs amounting to $492,735[183]. - The directors have prepared the financial statements on a going concern basis, contingent on the ability to secure sufficient cash from various sources[194].

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF T ...

[Key Information](index=4&type=section&id=Item%203.%20Key%20Information) This section presents selected financial data and details the company's significant financial, operational, and intellectual property risks [Selected Financial Data](index=4&type=section&id=A.%20Selected%20financial%20data) Selected financial data for fiscal years 2016-2020, prepared under IFRS in A$, shows consistent net losses increasing to A$12.5 million in 2020 Consolidated Financial Summary (2018-2020, A$'000) | Financial Metric | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | **Profit or Loss** | | | | | Revenue and other income | 1,061 | 1,565 | 13,108 | | Loss after income tax expense | (12,467) | (10,270) | (6,039) | | Basic loss per share (cents) | (17.07) | (17.86) | (12.48) | | **Financial Position** | | | | | Cash and cash equivalents | 8,764 | 5,434 | 5,956 | | Total assets | 23,063 | 21,177 | 28,175 | | Net assets/Equity | 14,125 | 14,195 | 19,242 | - The financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the IASB[25](index=25&type=chunk) [Risk Factors](index=6&type=section&id=D.%20Risk%20factors) The company faces significant financial, operational, developmental, commercial, intellectual property, and securities-related risks [Financial and Capital Risks](index=6&type=section&id=Risks%20Related%20to%20Our%20Financial%20Condition%20and%20Capital%20Requirement) The company faces substantial financial and capital risks, including a history of net losses and dependence on future capital raising - The company has incurred significant net losses, including **A$12.5 million** for the fiscal year ended June 30, 2020, and anticipates continued losses for the foreseeable future[31](index=31&type=chunk) - As of June 30, 2020, accumulated losses totaled **A$36.2 million**[32](index=32&type=chunk) - Existing cash and cash equivalents are expected to be sufficient to fund R&D activities until approximately the first quarter of calendar 2022, making the company's going concern status dependent on its ability to raise more capital[41](index=41&type=chunk) - The company's R&D tax rebate from the Australian government decreased from **A$1.4 million** in fiscal 2019 to **A$1.0 million** in fiscal 2020, with further declines expected as more R&D expenditure occurs in the U.S[44](index=44&type=chunk)[159](index=159&type=chunk) [Business Operation Risks](index=9&type=section&id=Risks%20Related%20to%20Our%20Business%20Operations) Operational risks include reliance on key personnel, IT system vulnerabilities, and uncertainty regarding the utilization of carried-forward tax losses - The company's success is highly dependent on the continued service of key management and specialized technical personnel[51](index=51&type=chunk) - Internal and third-party IT systems are vulnerable to cyber-attacks and other failures, which could disrupt product development programs and lead to data loss[55](index=55&type=chunk) - The ability to utilize substantial carried-forward tax losses is uncertain, as it depends on meeting either the continuity of ownership test (COT) or the same business test (SBT) under Australian law[56](index=56&type=chunk)[57](index=57&type=chunk) [Product Development and Regulatory Risks](index=11&type=section&id=Risks%20Related%20to%20the%20Product%20Development%20and%20Regulatory%20Approval%20of%20Our%20Product%20Candidates) Significant risks exist in product development and regulatory approval, as preclinical success does not guarantee clinical trial outcomes or market exclusivity - The FDA granted Orphan Drug Designation for Cantrixil in ovarian cancer (April 2015), paxalisib in glioblastoma (February 2018), and paxalisib in malignant glioma (August 2020)[60](index=60&type=chunk) - There is a significant risk that positive results from preclinical studies may not be replicated in human clinical trials, a common setback in the biotechnology industry[62](index=62&type=chunk) [Commercialization Risks](index=12&type=section&id=Risks%20Related%20to%20Commercialization%20of%20Our%20Product%20Candidates) Commercialization risks include challenges in securing partnerships, achieving market acceptance, and competing with larger, better-resourced companies - The company must establish contractual arrangements for manufacturing, marketing, and distribution, but there is no assurance of negotiating commercially acceptable agreements[65](index=65&type=chunk)[66](index=66&type=chunk) - The company faces competition from large pharmaceutical and biotechnology companies that have significantly greater capital resources, larger R&D staff, and more experience in drug development and marketing[69](index=69&type=chunk) [Intellectual Property Risks](index=13&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) Intellectual property risks involve challenges in patent protection, potential invalidation of patents, and difficulties in enforcing IP rights internationally - The company relies on a combination of patents, trade secret protection, and confidentiality agreements to protect its product candidates[70](index=70&type=chunk) - Patent applications may fail to issue, or issued patents may be invalidated through legal challenges, which could impair the company's ability to prevent competition[71](index=71&type=chunk) - Enforcing patent rights in certain countries, particularly developing ones, is difficult and costly, which could allow competitors to infringe on the company's IP[77](index=77&type=chunk) [Third-Party Reliance Risks](index=14&type=section&id=Risks%20Related%20to%20Our%20Reliance%20on%20Third%20Parties) The company's reliance on third parties for preclinical, clinical, and manufacturing services poses significant operational and cost control risks - The company relies on third parties, including laboratories, investigators, and CROs, to conduct all of its preclinical and clinical studies[78](index=78&type=chunk) - Manufacturing of drug candidates is outsourced to third parties, meaning the company has no direct control over production costs, which could increase and adversely affect future profitability[80](index=80&type=chunk) [Securities Risks](index=15&type=section&id=Risks%20Related%20to%20our%20Securities) Securities risks include high stock price volatility, potential NASDAQ delisting, and adverse U.S. tax consequences from PFIC classification - The trading price of the company's ordinary shares and ADSs is highly volatile and subject to broad market fluctuations[82](index=82&type=chunk) - There is a risk of being classified as a Passive Foreign Investment Company (PFIC), which would result in adverse U.S. federal income tax consequences for U.S. holders[87](index=87&type=chunk)[311](index=311&type=chunk) - The company is subject to Australian takeover laws, which prohibit acquisitions that would lead to a person's voting power exceeding 20%, potentially discouraging takeover offers[89](index=89&type=chunk) [Company Information](index=17&type=section&id=Item%204.%20Information%20on%20the%20Company) This section details the company's history, business operations, drug pipeline, regulatory environment, recent developments, and organizational structure [History and Development](index=17&type=section&id=A.%20History%20and%20development%20of%20the%20Company) Kazia Therapeutics Limited, an Australian oncology biotechnology company, is listed on ASX and NASDAQ via ADSs - Kazia Therapeutics Limited was incorporated in March 1994 in New South Wales, Australia[90](index=90&type=chunk) - The company's Ordinary Shares are listed on the ASX under 'KZA', and its ADSs trade on NASDAQ under 'KZIA', with each ADS representing ten Ordinary Shares[92](index=92&type=chunk) [Business Overview](index=17&type=section&id=B.%20Business%20overview) Kazia is an oncology-focused biotechnology company developing paxalisib for brain cancers and Cantrixil for ovarian cancer [Drug Pipeline and Clinical Trials](index=17&type=section&id=Drug%20Pipeline%20and%20Clinical%20Trials) The company's drug pipeline includes paxalisib for brain cancers and Cantrixil for ovarian cancer, both in clinical trials with promising interim results - The lead drug candidate is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K/Akt/mTOR pathway, being developed for glioblastoma (GBM) and other brain cancers[93](index=93&type=chunk)[95](index=95&type=chunk) - Interim data from the Phase II trial of paxalisib in GBM showed a median overall survival (OS) of **17.7 months**, which compares favorably to the **12.7 months** associated with the existing standard of care, temozolomide[99](index=99&type=chunk) - In August 2020, the FDA awarded paxalisib Fast Track Designation for glioblastoma and Rare Pediatric Disease Designation for DIPG, a rare childhood brain cancer[95](index=95&type=chunk) - The company's second clinical asset, Cantrixil, is in a Phase I trial for ovarian cancer, which reported an overall response rate (ORR) of **19%** in an interim analysis[94](index=94&type=chunk)[110](index=110&type=chunk) - The company has adopted the GBM AGILE platform study as the pivotal trial for registration of paxalisib, with recruitment expected to commence in late 2020[105](index=105&type=chunk) [Regulatory Environment](index=19&type=section&id=Regulatory%20Environment) The company's products are subject to stringent regulatory approval processes by authorities like the FDA, TGA, and EMA - In the U.S., the FDA drug approval process generally involves preclinical testing, submission of an IND application, and successful completion of Phase I, II, and III clinical trials before an NDA can be filed[124](index=124&type=chunk)[131](index=131&type=chunk) - In Australia, pharmaceutical products must be approved by the Therapeutic Goods Administration (TGA) and included in the Australian Register of Therapeutic Goods (ARTG)[113](index=113&type=chunk) - In the European Union, marketing authorizations can be obtained through a centralized procedure via the European Medicines Agency (EMA) or through national procedures[140](index=140&type=chunk) [Recent Developments (Fiscal 2020)](index=23&type=section&id=Recent%20Developments%20(Fiscal%202020)) Fiscal 2020 saw increased focus on clinical programs, with significant capital raised to fund the pivotal GBM AGILE study - Raised **A$3.7 million** (net) in November 2019 and **A$8.4 million** (net) in April/May 2020 through share placements and a Share Purchase Plan[146](index=146&type=chunk) - Post-balance date, in October 2020, the company raised an additional **A$23 million** (net) to fund its participation in the GBM AGILE study[147](index=147&type=chunk) - Cash outlay for clinical programs increased to **72%** of the total cash outlay for fiscal 2020, up from **63%** in the prior year, reflecting the company's strategic focus[149](index=149&type=chunk) [Organizational Structure](index=24&type=section&id=C.%20Organizational%20structure) Kazia Therapeutics Limited operates as an Australian parent company with four wholly-owned subsidiaries in Australia and the United States Company Subsidiaries | Name | Country of incorporation | | :--- | :--- | | Kazia Laboratories Pty Ltd | Australia | | Kazia Research Pty Ltd | Australia | | Kazia Therapeutics Inc. | United States (Delaware) | | Glioblast Pty Ltd | Australia | [Operating and Financial Review](index=25&type=section&id=Item%205.%20Operating%20and%20Financial%20Review%20and%20Prospects) This section reviews the company's operating results, liquidity, capital resources, R&D activities, and future outlook [Operating Results](index=25&type=section&id=A.%20Operating%20results) Net loss increased to A$12.5 million in fiscal 2020, driven by higher R&D expenses and a reduced R&D tax rebate - Research and development expenses increased by **47%** to **A$9.5 million** in fiscal 2020 from **A$6.5 million** in fiscal 2019, largely due to the paxalisib glioblastoma trial[161](index=161&type=chunk) - General and administrative costs remained stable, decreasing slightly by **3%** to **A$3.7 million** in fiscal 2020[162](index=162&type=chunk) - The net loss after tax increased to **A$12.5 million** in fiscal 2020, compared to **A$10.3 million** in fiscal 2019, due to higher R&D spending and a lower R&D tax rebate[163](index=163&type=chunk) - The R&D tax rebate decreased from **A$1.4 million** in FY2019 to **A$1.0 million** in FY2020 because a majority of R&D expenditure occurred in the United States and was therefore ineligible[159](index=159&type=chunk) [Liquidity and Capital Resources](index=26&type=section&id=B.%20Liquidity%20and%20capital%20resources) As of June 30, 2020, the company held A$8.8 million in cash, funding operations primarily through equity offerings and grants - As of June 30, 2020, the company had cash and cash equivalents of **A$8.8 million** and no borrowings[166](index=166&type=chunk)[167](index=167&type=chunk) Cash Flow Summary (A$ thousands) | (in A$ thousands) | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | Net cash used in operating activities | (8,809) | (6,714) | (8,661) | | Net cash from investing activities | — | 2,359 | 150 | | Net cash from financing activities | 12,139 | 3,815 | — | - Financing activities in fiscal 2020 and 2019 consisted of private placements of ordinary shares and Share Purchase Plans, raising **A$12.1 million** and **A$3.8 million**, respectively[172](index=172&type=chunk) [Research and Development](index=28&type=section&id=C.%20Research%20and%20development,%20Patents%20and%20Licenses,%20etc.) R&D expenses, the company's primary cost, increased to A$9.5 million in fiscal 2020 and are expected to continue rising - R&D costs are expensed as incurred, as development programs are not yet considered technically or commercially feasible to justify capitalization[182](index=182&type=chunk) R&D Expenditure (A$ million) | Fiscal Year | R&D Expense | | :--- | :--- | | 2020 | A$9.5 million | | 2019 | A$6.5 million | | 2018 | A$9.8 million | [Trend Information and Outlook](index=28&type=section&id=D.%20Trend%20Information) Fiscal 2021 outlook includes final clinical trial results for paxalisib and Cantrixil, and commencement of the GBM AGILE pivotal study - Key expectations for fiscal 2021 include: - Final results from the Phase II paxalisib (glioblastoma) trial - Final results from the Phase I Cantrixil (ovarian cancer) trial - Interim results from the Phase I paxalisib (DIPG) trial - Commencement of recruitment for the GBM AGILE pivotal study of paxalisib[186](index=186&type=chunk)[189](index=189&type=chunk) [Directors, Senior Management and Employees](index=30&type=section&id=Item%206.%20Directors,%20Senior%20Management%20and%20Employees) This section covers compensation, board practices, employee details, and share ownership for directors and senior management [Compensation](index=31&type=section&id=B.%20Compensation) Executive compensation includes fixed salary, cash bonuses, and ESOP, with total KMP compensation at A$1.65 million in fiscal 2020 - The executive remuneration framework consists of three components: fixed remuneration, short-term cash bonuses, and share-based payments via the ESOP[198](index=198&type=chunk) FY2020 Key Management Personnel Compensation (A$) | Name | Title | Cash Salary & Fees | Cash Bonus | Share-based payments | Total | | :--- | :--- | :--- | :--- | :--- | :--- | | I Ross | Chairman | 135,272 | — | — | 135,272 | | B Carmine | Non-Exec Director | 75,000 | — | — | 82,125 | | S Coffey | Non-Exec Director | 75,000 | — | — | 82,125 | | J Garner | CEO | 473,000 | 180,000 | 206,465 | 944,923 | | G Heaton | Director of Finance | 195,000 | 17,500 | 10,745 | 250,708 | | K Hill | Company Secretary | 127,875 | 15,000 | 12,826 | 155,701 | | **Total** | | **1,081,147** | **212,500** | **230,036** | **1,650,854** | - During fiscal 2020, the company issued **1,450,000** share options under its ESOP, with **1,300,000** granted to Key Management Personnel[204](index=204&type=chunk) [Board Practices](index=35&type=section&id=C.%20Board%20Practices) The Board of Directors, comprising four members with three independent non-executives, oversees governance through two key committees - The Board consists of four directors, three of whom are non-executive and considered independent: Iain Ross (Chairman), Bryce Carmine, and Steven Coffey[223](index=223&type=chunk)[229](index=229&type=chunk) - The Board has two key committees: the Audit, Risk and Governance Committee and the Remuneration and Nomination Committee[230](index=230&type=chunk) - Both committees are composed of the three independent directors, with Steven Coffey chairing the Audit Committee and Bryce Carmine chairing the Remuneration Committee[232](index=232&type=chunk)[234](index=234&type=chunk) [Employees](index=38&type=section&id=D.%20Employees) As of June 30, 2020, the company maintained 5.3 FTE employees, stable across the past three fiscal years Full-Time Equivalent Employees by Function | Category of Activity | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | Research and Development | 3.6 | 3.6 | 3.6 | | Finance and Administration | 1.7 | 1.7 | 1.7 | | **Total** | **5.3** | **5.3** | **5.3** | [Share Ownership](index=39&type=section&id=E.%20Share%20Ownership) Directors and KMP collectively held 1,707,768 ordinary shares and 1,762,000 options at the end of fiscal 2020 - At the end of fiscal 2020, Directors and KMP held a total of **1,707,768** ordinary shares[240](index=240&type=chunk) - At the end of fiscal 2020, Directors and KMP held a total of **1,762,000** options over ordinary shares[241](index=241&type=chunk) [Major Shareholders and Related Party Transactions](index=40&type=section&id=Item%207.%20Major%20Shareholders%20and%20Related%20Party%20Transactions) This section identifies major shareholders as of October 2020 and confirms no significant related party transactions in fiscal 2020 Major Shareholders (as of October 14, 2020) | 5% or greater shareholders | Ordinary shares beneficially owned | % | | :--- | :--- | :--- | | Hishenk Pty Limited and associated entities | 18,570,000 | 16.1% | | Platinum International Healthcare Fund | 11,356,760 | 9.9% | | Quest Asset Partners Pty Ltd | 7,215,790 | 6.3% | - As of October 12, 2020, **31,302,996** ordinary shares (**27.1%** of outstanding shares) were held in the form of ADSs[244](index=244&type=chunk) - The company did not enter into any significant transactions or loans with related parties during fiscal 2020[246](index=246&type=chunk) [Financial Information](index=40&type=section&id=Item%208.%20Financial%20Information) This section references full financial statements, notes an ongoing IP legal proceeding, and confirms no dividends paid - The company is engaged in an ongoing legal proceeding to prosecute its Intellectual Property (IP) rights against an Austrian company, APOtrend, with the outcome and potential financial impact currently uncertain[249](index=249&type=chunk) - No dividends were paid, recommended, or declared during the fiscal years 2020, 2019, or 2018[250](index=250&type=chunk) [Additional Information](index=41&type=section&id=Item%2010.%20Additional%20Information) This section provides additional details on material contracts and taxation matters [Material Contracts](index=45&type=section&id=C.%20Material%20contracts) Material contracts include the 2016 paxalisib licensing agreement with Genentech and the 2020 GBM AGILE study agreement with GCAR - In October 2016, the company entered into a worldwide licensing agreement with Genentech for paxalisib (GDC-0084), paying an upfront fee of **US$5 million**, with additional performance-related milestones and royalties[285](index=285&type=chunk) - In October 2020, the company entered into an agreement with the Global Coalition for Adaptive Research (GCAR) to include paxalisib in the GBM AGILE pivotal study, which included an upfront payment of **US$5 million**[290](index=290&type=chunk) [Taxation](index=47&type=section&id=E.%20Taxation) This section outlines U.S. and Australian tax implications for shareholders, including potential PFIC classification and dividend/capital gains tax rules - **U.S. Tax Risk:** The company believes it may be treated as a Passive Foreign Investment Company (PFIC) for its 2020 taxable year, which could result in adverse U.S. federal income tax consequences for U.S. holders[311](index=311&type=chunk) - **Australian Dividend Tax:** Unfranked dividends paid to non-Australian shareholders are subject to withholding tax, which is generally limited to **15%** for U.S. residents under the current tax treaty[320](index=320&type=chunk) - **Australian Capital Gains Tax:** Non-Australian shareholders are generally not subject to Australian capital gains tax on the sale of shares unless they hold **10%** or more of the company's issued capital[322](index=322&type=chunk) [Market Risk Disclosures](index=52&type=section&id=Item%2011.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's primary market risks are interest rate and foreign currency exposure, managed through natural hedging without derivatives - The company is exposed to interest rate risk on its cash investments and foreign currency risk, primarily with respect to the U.S. dollar[336](index=336&type=chunk)[340](index=340&type=chunk) - Foreign exchange risk is managed through natural hedging; the company does not currently use derivative financial instruments for this purpose[341](index=341&type=chunk) [Controls and Procedures](index=54&type=section&id=Item%2015.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of June 30, 2020 - Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2020[353](index=353&type=chunk) - Based on an evaluation using the COSO 2013 framework, management concluded that the company's internal control over financial reporting was effective as of June 30, 2020[354](index=354&type=chunk) [Corporate Governance](index=54&type=section&id=Item%2016G.%20Corporate%20Governance) This section details corporate governance, including an audit committee financial expert, a Code of Ethics, and NASDAQ exemptions for foreign private issuers - The Board of Directors has determined that Steven Coffey qualifies as an "audit committee financial expert"[360](index=360&type=chunk) - The company has adopted a Code of Ethics and Business Conduct applicable to all employees and directors[361](index=361&type=chunk) - As a foreign private issuer, Kazia is exempt from certain NASDAQ corporate governance standards, such as shareholder quorum requirements, and follows Australian practices instead[372](index=372&type=chunk)[375](index=375&type=chunk) [Financial Statements](index=57&type=section&id=Item%2018.%20Financial%20Statements) This section presents the company's audited consolidated financial statements for fiscal years 2018-2020, prepared under IFRS [Consolidated Statement of Profit or Loss](index=62&type=section&id=Consolidated%20statements%20of%20profit%20or%20loss%20and%20other%20comprehensive%20income) The company reported a net loss of A$12.47 million in fiscal 2020, primarily due to increased research and development expenses Key Profit & Loss Items (A$'000) | Item | 2020 | 2019 | | :--- | :--- | :--- | | Research and development expense | (9,494) | (6,475) | | General and administrative expense | (3,690) | (3,785) | | **Loss before income tax** | **(12,765)** | **(10,568)** | | Income tax benefit | 298 | 298 | | **Loss after income tax** | **(12,467)** | **(10,270)** | - Basic and diluted loss per share for fiscal 2020 was **(17.07) cents**, compared to **(17.86) cents** in fiscal 2019[394](index=394&type=chunk) [Consolidated Statement of Financial Position](index=64&type=section&id=Consolidated%20statements%20of%20financial%20position) As of June 30, 2020, total assets were A$23.06 million, with A$8.76 million in cash and A$12.41 million in intangibles Key Balance Sheet Items (A$'000) | Item | 30 June 2020 | 30 June 2019 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | 8,764 | 5,434 | | Intangibles | 12,410 | 13,494 | | **Total Assets** | **23,063** | **21,177** | | **Liabilities** | | | | Total current liabilities | 5,067 | 1,900 | | Total non-current liabilities | 3,871 | 5,082 | | **Total Liabilities** | **8,938** | **6,982** | | **Net Assets (Equity)** | **14,125** | **14,195** | [Consolidated Statement of Cash Flows](index=67&type=section&id=Consolidated%20statements%20of%20cash%20flows) Fiscal 2020 saw A$8.81 million cash used in operations, offset by A$12.14 million from financing, increasing cash to A$8.76 million Cash Flow Summary (A$'000) | Cash Flow Activity | 2020 | 2019 | | :--- | :--- | :--- | | Net cash used in operating activities | (8,810) | (6,714) | | Net cash from investing activities | — | 2,359 | | Net cash from financing activities | 12,139 | 3,816 | | **Net increase/(decrease) in cash** | **3,329** | **(539)** | | **Cash at end of year** | **8,764** | **5,434** |

Not Applicable Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...